Exelixis Inc（EXEL）财务数据EXELExelixis Inc

Exelixis Inc (EXEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is CABOMETYX, accounting for 90.8% of total sales, equivalent to $570.65M. Other significant revenue streams include License revenues and COMETRIQ. Understanding this composition is critical for investors evaluating how EXEL navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Exelixis Inc maintains a gross margin of 96.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 39.51%, while the net margin is 33.73%. These profitability ratios, combined with a Return on Equity (ROE) of 44.39%, provide a clear picture of how effectively EXEL converts its operational activities into shareholder value.

In the context of the broader market, EXEL competes directly with industry leaders such as ASND and JAZZ. With a market capitalization of $14.82B, it holds a significant position in the sector. When comparing efficiency, EXEL's gross margin of 96.71% stands against ASND's 91.85% and JAZZ's 76.30%. Such benchmarking helps identify whether Exelixis Inc is trading at a premium or discount relative to its financial performance.

Exelixis has demonstrated strong revenue growth, with Q2 2026 revenue reported at $628.69 million and a net income of $212 million, reflecting a robust business model in the oncology sector. The gross margin remains high at 96.71%, indicating efficient cost management.